Your Source for Venture Capital and Private Equity Financings

Venture Capital News: HI-Bio Launches With $120M

SOUTH SAN FRANCISCO, CA, Human Immunology Biosciences announced its launch with $120 million in financing.
Human Immunology Biosciences, a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), announced its launch with $120 million in financing. The company was incubated by ARCH Venture Partners and Monograph Capital, joined by Jeito Capital and unnamed institutional investors and family offices.

Human Immunology Biosciences, is a clinical-stage biotechnology company focused on discovering and developing precision medicines for people suffering from immune-mediated diseases (IMDs).
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000 startups and 5,000 VC investors

Featured Reading